Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

Barby Pickett, John Kurhanewicz, Fergus Coakley, Katsuto Shinohara, Beverly Fein, MacK Roach

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Purpose To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy. Methods and materials A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir. Results Of the 55 patients, 70% had negative MRSI and 30% had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found. Conclusion When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign "blip" from local recurrence.

Original languageEnglish (US)
Pages (from-to)1047-1055
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume60
Issue number4
DOIs
StatePublished - Nov 15 2004
Externally publishedYes

Fingerprint

antigens
Prostate-Specific Antigen
magnetic resonance
radiation therapy
Prostatic Neoplasms
Magnetic Resonance Spectroscopy
Radiotherapy
cancer
Magnetic Resonance Imaging
evaluation
Biopsy
spectroscopy
atrophy
metabolism
serums
Atrophy
Prostate
confidence
Spectrum Analysis
Recurrence

Keywords

  • External beam radiotherapy
  • Magnetic resonance imaging
  • Prostate cancer
  • Spectroscopy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. / Pickett, Barby; Kurhanewicz, John; Coakley, Fergus; Shinohara, Katsuto; Fein, Beverly; Roach, MacK.

In: International Journal of Radiation Oncology Biology Physics, Vol. 60, No. 4, 15.11.2004, p. 1047-1055.

Research output: Contribution to journalArticle

Pickett, Barby ; Kurhanewicz, John ; Coakley, Fergus ; Shinohara, Katsuto ; Fein, Beverly ; Roach, MacK. / Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. In: International Journal of Radiation Oncology Biology Physics. 2004 ; Vol. 60, No. 4. pp. 1047-1055.
@article{a188000357eb408a971a10d28c5c2f8d,
title = "Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer",
abstract = "Purpose To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy. Methods and materials A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir. Results Of the 55 patients, 70{\%} had negative MRSI and 30{\%} had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found. Conclusion When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign {"}blip{"} from local recurrence.",
keywords = "External beam radiotherapy, Magnetic resonance imaging, Prostate cancer, Spectroscopy",
author = "Barby Pickett and John Kurhanewicz and Fergus Coakley and Katsuto Shinohara and Beverly Fein and MacK Roach",
year = "2004",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2004.05.015",
language = "English (US)",
volume = "60",
pages = "1047--1055",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

AU - Pickett, Barby

AU - Kurhanewicz, John

AU - Coakley, Fergus

AU - Shinohara, Katsuto

AU - Fein, Beverly

AU - Roach, MacK

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Purpose To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy. Methods and materials A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir. Results Of the 55 patients, 70% had negative MRSI and 30% had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found. Conclusion When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign "blip" from local recurrence.

AB - Purpose To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy. Methods and materials A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir. Results Of the 55 patients, 70% had negative MRSI and 30% had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found. Conclusion When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign "blip" from local recurrence.

KW - External beam radiotherapy

KW - Magnetic resonance imaging

KW - Prostate cancer

KW - Spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=7444225321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444225321&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.05.015

DO - 10.1016/j.ijrobp.2004.05.015

M3 - Article

VL - 60

SP - 1047

EP - 1055

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -